BioMarin Pharmaceutical has committed to investing €60m into the expansion of its Shanbally, Cork facility.
The company will build a new four-storey laboratory facility, meaning it can boost the site's production capacity, which produces targeted therapies for genetic conditions.
Through this expansion, BioMarin will also have room for further expansion.
The Shanbally facility is the company's first manufacturing site out of the US, and has experienced significant expansion in recent years.
Last year, the company opened an aseptic production facility, which enahnced the production of both commercial and clinical products.
"This investment in our Cork facility reflects our ongoing commitment to enhancing our industry-leading global manufacturing capabilities and supporting the growth of our innovative medicines for our people living with rare conditions around the world," said Evelyn Marchany Garcia, Senior Vice President, Chief Quality Officer, BioMarin Pharmaceutical.
"The Shanbally facility plays a crucial role in our global network, and this expansion emphasises our confidence in Ireland's skilled workforce and the strategic importance of this site to BioMarin’s long-term success," they added.
Michael Lohan, CEO of IDA Ireland, said that as a global leader in the biopharmaceutical sector, BioMarin's ongoing investment in Ireland is a welcome endorsement of the country's position globally as a location of choice for biopharmaceuticals and a trailblazer in advancing healthcare solutions.
"By opening this new quality control and process development laboratory, BioMarin will create new opportunities for collaboration, talent development and growth, ensuring that the life sciences sector in Ireland continues to make an impact on patients’ lives worldwide," the IDA CEO added.